Medtronic plc, a global leader in medical technology, provides extensive device-based medical therapies. With strong portfolios in cardiovascular, medical surgical, neuroscience, and diabetes sectors, the company has positioned itself well. The stock shows potential, backed by innovative product offerings and a robust market presence.
The fundamental rating of Medtronic plc reflects its strengths in financial health and market standing, with a focus on its cash flow and return metrics.
Category | Score | Visualization |
---|---|---|
Discounted Cash Flow | 4 | |
Return On Equity | 4 | |
Return On Assets | 4 | |
Debt To Equity | 2 | |
Price To Earnings | 1 | |
Price To Book | 3 |
Historical data depicts stability in Medtronic's fundamental scores, reflecting consistent financial management over time.
Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
---|---|---|---|---|---|---|---|
Current | 3 | 4 | 4 | 4 | 2 | 1 | 3 |
2025-08-29 | 3 | 4 | 4 | 4 | 2 | 1 | 3 |
Analysts have set a unified price target for Medtronic plc, indicating aligned expectations regarding its market performance.
High | Low | Median | Consensus |
---|---|---|---|
115 | 115 | 115 | 115 |
The sentiment among analysts is predominantly positive, with a strong inclination towards buying, supported by the company's strategic growth trajectory.
Recommendation | Number | Visualization |
---|---|---|
Strong Buy | 1 | |
Buy | 27 | |
Hold | 21 | |
Sell | 0 | |
Strong Sell | 0 |
Medtronic plc exhibits a resilient financial profile, supported by a diverse product line and strategic market strategies. The company's stability in fundamentals and favorable analyst ratings position it well for future growth. However, investors should remain cautious of potential fluctuations in market conditions and regulatory environments. Overall, Medtronic provides promising opportunities with manageable risk levels for prospective stakeholders.